MedTrace Logo

A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)

NCT05863819 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-10-18

No results posted yet for this study

Summary

The main aim of this study is to learn about the time from start of mobocertinib to end of treatment with mobocertinib for any reason in Chinese adults with lung cancer who carry a certain gene mutation (epidermial growth factor receptor - EGFR exon 20 insertion mutation) during normal clinical practice.

Participants will be treated with mobocertinib as per their normal routine. Data for this study will be collected from the available medical records of a participant.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

OTHER

No Intervention

As this is an observational study, no intervention will be administered in this study.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-30
Primary Completion
2026-12-01
Completion
2027-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05863819 on ClinicalTrials.gov